A TriNetX analysis of over a million IBD patients was presented at the ASCO Breakthrough Meeting. ASCO's chief medical officer called the evidence preliminary.
Recap by typeshit. Full story at The ASCO Post.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
Over four months, people without structured support regained 10.75% of body weight. Tufts researcher Kelseanna Hollis-Hansen and Harvard's Dr Caroline Apovian weigh in.
Researchers in Vienna reported nail detachment in 39% of GLP-1 users versus 9% of non-users. Authors say the self-reported data shows a link, not proof of cause.
Loading…